Peripheral artery disease: potential role of ACE-inhibitor therapy

Egle Corrado, Salvatore Novo, Giuseppe Coppola, Rosa Maria Grisanti

Risultato della ricerca: Articlepeer review

14 Citazioni (Scopus)

Abstract

Subjects with peripheral arterial disease (PAD) of the lower limbs are at high risk for cardiovascular and cerebrovascular events and the prevalence of coronary artery disease in such patients is elevated. Recent studies have shown that regular use of cardiovascular medications, such as therapeutic and preventive agents for PAD patients, seems to be promising in reducing long-term mortality and morbidity. The angiotensin-converting-enzyme (ACE) system plays an important role in the pathogenesis and progression of atherosclerosis, and ACE-inhibitors (ACE-I) seem to have vasculoprotective and antiproliferative effects as well as a direct antiatherogenic effect. ACE-I also promote the degradation of bradykinin and the release of nitric oxide, a potent vasodilator; further, thay have shown important implications for vascular oxidative stress. Other studies have suggested that ACE-I may also improve endothelial dysfunction. ACE-I are useful for reducing the risk of cardiovascular events in clinical and subclinical PAD. Particularly, one agent of the class (ie, ramipril) has shown in many studies to able to significantly reduce cardiovascular morbidity and mortality in patients with PAD
Lingua originaleEnglish
pagine (da-a)1179-1187
Numero di pagine9
RivistaVascular Health and Risk Management
Volume4
Stato di pubblicazionePublished - 2008

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Entra nei temi di ricerca di 'Peripheral artery disease: potential role of ACE-inhibitor therapy'. Insieme formano una fingerprint unica.

Cita questo